Proton pump inhibitors on pancreatic cancer risk and survival

Cancer Epidemiology

Volumn 46, Issue , 2017, Pages 80-84

  Kearns, Malcolm D ^a   Boursi, Ben ^a,b,c   Yang, Yu Xiao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Pancreatic cancer; Proton pump inhibitors; Risk; Survival

Indexed keywords

ALCOHOL; PROTON PUMP INHIBITOR;

AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PANCREAS CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; MORTALITY; PANCREAS TUMOR; PATHOLOGY;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 85007575329     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.12.006     Document Type: Article

References (52)

1. [1] Fitzgerald, R.C., Omary, M.B., Triadafilopoulos, G., Dynamic effects of acid on Barrett's esophagus: an ex vivo proliferation and differentiation model. J. Clin. Invest. 98:9 (1996), 2120–2128.
2. [2] Klinkenberg-Knol, E.C., Festen, H.P., Jansen, J.B., et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann. Intern. Med. 121:3 (1994), 161–167.
3. [3] Lamberts, R., Creutzfeldt, W., Stockmann, F., et al. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39:2 (1988), 126–135.
4. [4] Jansen, J.B., Klinkenberg-Knol, E.C., Meuwissen, S.G., et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99:3 (1990), 621–628.
5. [5] Hakanson, R., Bottcher, G., Sundler, F., et al. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion 35:Suppl. 1 (1986), 23–41.
6. [6] Kidd, M., Tang, L.H., Modlin, I.M., et al. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia. Digestion 62:2-3 (2000), 143–151.
7. [7] Qvigstad, G., Falkmer, S., Westre, B., et al. Clinical and histopathological tumour progression in ECL cell carcinoids (ECLomas). APMIS 107:12 (1999), 1085–1092.
8. [8] Waldum, H.L., Sandvik, A.K., Idle, J.R., Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 114:5 (1998), 1113–1115.
9. [9] Mattsson, H., Havu, N., Brautigam, J., et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology 100:2 (1991), 311–319.
10. [10] Henwood, M., Clarke, P.A., Smith, A.M., et al. Expression of gastrin in developing gastric adenocarcinoma. Br. J. Surg. 88:4 (2001), 564–568.
11. [11] Ho, A.C., Horton, K.M., Fishman, E.K., Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings. Clin. Imaging 24:4 (2000), 200–203.
12. [12] Poynter, D., Pick, C.R., Harcourt, R.A., et al. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 26:12 (1985), 1284–1295.
13. [13] Haigh, C.R., Attwood, S.E., Thompson, D.G., et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 124:3 (2003), 615–625.
14. [14] Bordi, C., D'Adda, T., Azzoni, C., et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am. J. Surg. Pathol. 19:Suppl. 1 (1995), S8–19.
15. [15] Cadiot, G., Lehy, T., Mignon, M., Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome. Acta Oncol. 32:2 (1993), 135–140.
16. [16] Delle Fave, G., Marignani, M., Moretti, A., et al. Hypergastrinemia and enterochromaffin-like cell hyperplasia. Yale J. Biol. Med. 71:3-4 (1998), 291–301.
17. [17] Lehy, T., Cadiot, G., Mignon, M., et al. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33:9 (1992), 1275–1279.
18. [18] Smith, J.P., Fantaskey, A.P., Liu, G., et al. Identification of gastrin as a growth peptide in human pancreatic cancer. Am. J. Physiol. 268:1 Pt 2 (1995), R135–41.
19. [19] Smith, J.P., Liu, G., Soundararajan, V., et al. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am. J. Physiol. 266:1 Pt 2 (1994), R277–83.
20. [20] Chau, I., Cunningham, D., Russell, C., et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer 94:8 (2006), 1107–1115.
21. [21] Chu, M., Kullman, E., Rehfeld, J.F., et al. Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster. Gut 40:4 (1997), 536–540.
22. [22] Brett, B.T., Smith, S.C., Bouvier, C.V., et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20:20 (2002), 4225–4231.
23. [23] Smith, A.M., Justin, T., Michaeli, D., et al. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin. Cancer Res. 6:12 (2000), 4719–4724.
24. [24] Bateman, D.N., Colin-Jones, D., Hartz, S., et al. Mortality study of 18 000 patients treated with omeprazole. Gut 52:7 (2003), 942–946.
25. [25] Garcia Rodriguez, L.A., Lagergren, J., Lindblad, M., Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55:11 (2006), 1538–1544.
26. [26] Poulsen, A.H., Christensen, S., McLaughlin, J.K., et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br. J. Cancer 100:9 (2009), 1503–1507.
27. [27] Ahn, J.S., Eom, C.S., Jeon, C.Y., et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J. Gastroenterol. 19:16 (2013), 2560–2568.
28. [28] Eslami, L., Nasseri-Moghaddam, S., Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?. Arch. Iran. Med. 16:8 (2013), 449–458.
29. [29] van Soest, E.M., van Rossum, L.G., Dieleman, J.P., et al. Proton pump inhibitors and the risk of colorectal cancer. Am. J. Gastroenterol. 103:4 (2008), 966–973.
30. [30] Chubak, J., Boudreau, D.M., Rulyak, S.J., et al. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol. Drug Saf. 18:7 (2009), 540–544.
31. [31] Robertson, D.J., Larsson, H., Friis, S., et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133:3 (2007), 755–760.
32. [32] Yang, Y.X., Hennessy, S., Propert, K., et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133:3 (2007), 748–754.
33. [33] Bradley, M.C., Murray, L.J., Cantwell, M.M., et al. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br. J. Cancer 106:1 (2012), 233–239.
34. [34] Lewis, J.D., Schinnar, R., Bilker, W.B., et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol. Drug Saf. 16:4 (2007), 393–401.
35. [35] Chisholm, J., The read clinical classification. BMJ, 300(6732), 1990, 1092.
36. [36] Bourke, A., Dattani, H., Robinson, M., Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform. Prim. Care 12:3 (2004), 171–177.
37. [37] Read, J., Read clinical classification. BMJ, 301(6742), 1990, 45.
38. [38] Lu, Y., Garcia Rodriguez, L.A., Malgerud, L., et al. New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. Br. J. Cancer 113:11 (2015), 1607–1614.
39. [39] Garcia-Rodriguez, L.A., Huerta-Alvarez, C., Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12:1 (2001), 88–93.
40. [40] Lewis, J.D., Bilker, W.B., Weinstein, R.B., et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol. Drug Saf. 14:7 (2005), 443–451.
41. [41] Lubin, J.H., Gail, M.H., Biased selection of controls for case-control analyses of cohort studies. Biometrics 40:1 (1984), 63–75.
42. [42] Klein, A.P., Lindstrom, S., Mendelsohn, J.B., et al. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One, 8(9), 2013, e72311.
43. [43] Bosetti, C., Lucenteforte, E., Silverman, D.T., et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann. Oncol. 23:7 (2012), 1880–1888.
44. [44] Zheng, W., McLaughlin, J.K., Gridley, G., et al. A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 4:5 (1993), 477–482.
45. [45] Silverman, D.T., Brown, L.M., Hoover, R.N., et al. Alcohol and pancreatic cancer in blacks and whites in the United States. Cancer Res. 55:21 (1995), 4899–4905.
46. [46] Nothlings, U., Wilkens, L.R., Murphy, S.P., et al. Body mass index and physical activity as risk factors for pancreatic cancer: the Multiethnic Cohort Study. Cancer Causes Control 18:2 (2007), 165–175.
47. [47] Michaud, D.S., Giovannucci, E., Willett, W.C., et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 286:8 (2001), 921–929.
48. [48] Hvid-Jensen, F., Nielsen, R.B., Pedersen, L., et al. Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting. Clin. Epidemiol. 5 (2013), 493–499.
49. [49] Porta, M., Fabregat, X., Malats, N., et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin. Transl. Oncol. 7:5 (2005), 189–197.
50. [50] Brat, D.J., Lillemoe, K.D., Yeo, C.J., et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 22:2 (1998), 163–169.
51. [51] Forgacs, I., Loganayagam, A., Overprescribing proton pump inhibitors. BMJ 336:7634 (2008), 2–3.
52. [52] Zink, D.A., Pohlman, M., Barnes, M., et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment. Pharmacol. Ther. 21:10 (2005), 1203–1209.